Mark Smith, Finch CEO
FDA lifts hold on Finch’s microbiome crapsule, as company looks to right ship
Finch Therapeutics’ lead program may fly again.
The microbiome company announced Thursday that the FDA lifted a two-month hold on clinical trials for its experimental …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
